• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

Safety

  • Print
  • Share
  • E-mail

Alimta (pemetrexed for injection) for intravenous use, 100 mg and 500 mg vials

Detailed View: Safety Labeling Changes Approved By FDA Center for Drug Evaluation and Research (CDER)

 

September 2013

Summary View

ADVERSE REACTIONS

Postmarketing Experience
  • These reactions occurred with Alimta when used as a single-agent and in combination therapies.
  • Blood and Lymphatic System — immune-mediated hemolytic anemia